Search the Newsreel

Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026)

Damora Therapeutics, Inc. (DMRA) filed a post-effective amendment to its S-3 registration statement on August 10, 2026. This amendment follows the company's redomestication from Delaware to the Cayman Islands on July 16, 2026, and clarifies that no new securities are being registered. The filing …

Can Metals Acquisition (ASX:MAC) Prove Mine Optimisation Copper?

Metals Acquisition (ASX:MAC) is attracting investor attention as the market evaluates its mine optimization strategies and copper cash flow potential. Key factors shaping expectations include operating evidence, financial discipline, and execution quality within Australia's evolving market. The article highlights that orebody quality, project returns, …

Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million

Damora Therapeutics reported a net loss of $31.2 million for Q2 2026, a significant increase from $3.4 million in the prior year, primarily due to soaring R&D expenses for its CLARITY-101 trial. Despite the widening loss, the company boasts strong liquidity with $540.5 million …

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings, reporting a loss of $0.39 per share, which surpassed analysts' consensus estimate of a $0.45 loss by $0.06. Following the announcement, shares fell 1.3% to $29.54, resulting in a market capitalization of approximately $1.82 …

Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Damora Therapeutics, Inc. announced its financial results for the second quarter and first six months of 2026, ending June 30th. The company reported a significant increase in net loss for both periods compared to the previous year. For the second quarter, the net loss …

Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026

Damora Therapeutics, Inc. Common Stock (DMRA) reported Q2 2026 earnings on August 10, 2026, with an EPS of -$0.39, beating the consensus estimate of -$0.45. The company's earnings are projected to decrease in the next year, from ($2.06) to ($2.14) per share. The article …

Levi & Korsinsky Urges Freeport-McMoRan Inc. (FCX) Shareholders to Act Before Lead Plaintiff Deadline January 12, 2026

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Freeport-McMoRan Inc. (FCX) on behalf of investors who suffered losses due to alleged securities fraud between February 15, 2022, and September 24, 2025. The lawsuit claims Freeport-McMoRan Inc. made false statements and …

Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)?

Damora Therapeutics (DMRA) has initiated its Phase 1/1b CLARITY-101 trial for DMR-001, a first-in-class antibody targeting mutant calreticulin in myelofibrosis and essential thrombocythemia. This trial launch de-risks execution and provides a clear catalyst with mid-2027 data, though risks remain due to the company's early-stage, …

Freeport McMoRan Stock And 2 Copper Picks Trading Below Fair Value

Weekly Top Stories: Copper Surge, $40 Trillion Debt, Jobs, Tariffs And China Minerals - Freeport-McMoRan

This article summarizes key economic stories from the past week, highlighting copper's surge as an indicator of a booming economy, the U.S. national debt approaching $40 trillion, unexpected market gains despite job losses, and the Trump administration's efforts to reduce reliance on Chinese minerals. …

NewEdge Advisors LLC Sells 50,516 Shares of Freeport-McMoRan Inc. $FCX

NewEdge Advisors LLC reduced its stake in Freeport-McMoRan Inc. by 14.7% in the first quarter, selling 50,516 shares and now owning 292,559 shares valued at $17.19 million. Other institutional investors, such as KBC Group NV and Franklin Resources Inc., increased their positions in the …

Análise e Previsão das Ações da Freeport-McMoRan Inc (FCX)

Freeport-McMoRan Inc (FCX) Aktuelle Aktien-News

Freeport-McMoRan Inc (FCX) Aktienanalyse & Prognose

Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026

This page provides an overview of Damora Therapeutics, Inc. Common Stock (DMRA) including its current stock price, trends in media mentions, and page views. It also offers tools and resources for investors to monitor the stock, receive alerts, and conduct further research. The stock …

Freeport-McMoRan Inc. $FCX Shares Purchased by Czech National Bank

Czech National Bank increased its stake in Freeport-McMoRan Inc. by 4.5% in the second quarter, bringing its total holdings to 409,185 shares valued at $25.73 million. Other institutional investors also modified their positions, with large firms like Vanguard Group and Fisher Asset Management holding …

Freeport-McMoRan (NYSE:FCX) Cut to "Hold" at Wall Street Zen

Wall Street Zen downgraded Freeport-McMoRan (NYSE:FCX) from "Buy" to "Hold," though the overall analyst consensus remains a "Moderate Buy" with an average price target of $70.27. The company recently reported strong quarterly earnings, beating EPS and revenue estimates, but also saw recent insider stock …

Freeport McMoRan (FCX) Stock Climbs As Profit Strength Meets Volume Risks

Freeport McMoRan (FCX) stock rose 2.1% after reporting strong Q2 2026 earnings, with basic EPS at US$0.68 and net income of US$984m, driven by copper, gold, and molybdenum production. Despite lower year-on-year revenue and copper production, profit increased significantly. The company faces both opportunities …

Shareholders of Freeport-McMoRan Inc. (FCX): Protect Your Rights Before January 12, 2026 - Contact Levi & Korsinsky

Levi & Korsinsky LLP has filed a class action securities lawsuit against Freeport-McMoRan Inc. (FCX) seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between February 15, 2022, and September 24, 2025. The lawsuit claims that Freeport-McMoRan made false …

Southern Copper Corp Stock (SCCO) Moved Up by 3.53% on Aug 7: Drivers Behind the Movement

Southern Copper Corp (SCCO) stock rose by 3.53% on August 7, driven by increasing global copper prices, tight inventories, and the company's low cash costs and strong margins. The article highlights how favorable mining policies in Latin America and the company's expansion projects are …

Copper Stocks to Watch as Electrification Demand Tightens Supply

This article examines three copper-focused stocks—Southern Peru Copper Corporation, First Quantum Minerals, and Freeport-McMoRan—that are positioned to benefit from surging copper demand driven by electrification and AI infrastructure. It highlights how these companies are affected by record copper prices and supply disruptions, while also …

PensionDanmark Pensionsforsikringsaktieselskab Sells 77,256 Shares of Freeport-McMoRan Inc. $FCX

PensionDanmark Pensionsforsikringsaktieselskab reduced its stake in Freeport-McMoRan Inc. by 18.7% in the second quarter, selling 77,256 shares and retaining 335,474 shares valued at approximately $21.1 million. Despite this reduction, institutional investors collectively own 80.77% of FCX. The company recently exceeded quarterly earnings expectations, reported …

Pacer Advisors Inc. Cuts Stake in Freeport-McMoRan Inc. $FCX

Pacer Advisors Inc. significantly reduced its stake in Freeport-McMoRan Inc. by 35.9% in the first quarter, selling 41,515 shares and retaining 74,212 shares valued at approximately $4.36 million. Despite this, other institutional investors have increased their holdings, and the company has shown strong earnings, …

Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim

Lori Firmani has filed a notice to sell up to 1,800 shares of Damara (DMRA) common stock through Maxim Group on the NASDAQ, with an aggregate value of $55,980.00 and an anticipated sale date of August 5, 2026. These shares are related to options …

Freeport-McMoRan Inc. $FCX Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. significantly reduced its stake in Freeport-McMoRan (NYSE:FCX) by 43.9% in the second quarter, selling over 2.3 million shares. Despite this, Freeport-McMoRan reported strong quarterly earnings, beating analyst expectations with an EPS of $0.74, and analysts maintain a "Moderate Buy" consensus …

Lost Money on Freeport-McMoRan Inc. (FCX)? Join Class Action Before January 12, 2026 - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Freeport-McMoRan Inc. (NYSE: FCX) on behalf of investors who suffered losses due to alleged securities fraud between February 15, 2022, and September 24, 2025. The lawsuit claims that Freeport-McMoRan made false statements …

Class Action Alert: Levi & Korsinsky Reminds Freeport-McMoRan Inc. (FCX) Investors of January 12, 2026 Deadline

Levi & Korsinsky LLP has issued a class action alert for investors of Freeport-McMoRan Inc. (NYSE: FCX), reminding them of the January 12, 2026 deadline to potentially recover losses from alleged securities fraud. The lawsuit claims Freeport-McMoRan made false statements regarding safety at its …

FREEPORT-MCMORAN INC 2Q 2026: Revenue $7.03B, EPS $0.68— 10-Q Summary

FREEPORT-MCMORAN INC (FCX) reported Q2 2026 results with revenues of $7.03 billion and diluted EPS of $0.68. The company saw increased realized copper and gold prices and strong operational performance in its U.S. mines, despite a decline in overall revenue and net income compared …

Freeport-McMoRan Inc. stock underperforms Thursday when compared to competitors

Freeport-McMoRan Inc. (FCX) shares dropped 1.74% on Thursday, closing at $68.18. This underperformance occurred during a generally down day for the stock market, with both the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's fall ended a three-day winning streak.

Damora Begins Testing Antibody Designed for Monthly Doses

Damora Therapeutics has initiated a global Phase 1/1b clinical trial (CLARITY-101) for DMR-001, an investigational monoclonal antibody targeting mutant calreticulin (mutCALR) in patients with essential thrombocythemia and myelofibrosis. Preclinical data showed DMR-001 has high binding affinity and a longer half-life, supporting once-monthly subcutaneous dosing. …

Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Damora Therapeutics, Inc. (DMRA) has not received any FDA approvals in the past two years, but its drug DMR-001 is currently under FDA review. The company recently announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial for DMR-001, an investigational monoclonal antibody …

Freeport-McMoRan Inc. $FCX Shares Sold by Edgestream Partners L.P.

Edgestream Partners L.P. significantly reduced its stake in Freeport-McMoRan Inc. ($FCX) by 83.4% in the first quarter, selling 22,366 shares and retaining 4,449. Despite this sale and recent insider selling, analyst sentiment remains largely positive with a "Moderate Buy" rating and several price target …

Freeport-McMoRan (FCX) equity awards move toward resale under Rule 144

A holder of Freeport-McMoRan Inc. common stock has filed a notice of proposed sales under Rule 144, covering shares held at Charles Schwab & Co., Inc. These shares are equity awards that became available to trade following restricted stock lapses on February 15, 2025, …

Freeport-McMoRan (FCX) insider Stephen T. Higgins details stock sale and awards

Freeport-McMoRan insider Stephen T. Higgins reported a stock sale of 7,550 shares for $475,650 on July 30, 2026. The filing also detailed previous equity compensation awards that vested as Restricted Stock Lapse on February 15, 2022 (5,846 shares) and February 15, 2023 (8,431 shares). …

Damora Therapeutics earnings on deck as rare blood cancer race heats up

Damora Therapeutics is set to release its second-quarter earnings, with analysts expecting a loss of 44 cents per share. The pre-revenue biotech is advancing its lead rare blood cancer treatment, DMR-001, towards clinical trials, facing competition from Incyte Corp.'s INCA033989. Investors will focus on …

Freeport-McMoRan, Inc. Revenue Breakdown – SWB:FPMB

This article provides a revenue breakdown for Freeport-McMoRan, Inc. (SWB:FPMB), detailing its top-performing segments and regional contributions. Last year, the company generated ‪22.06 B‬ EUR in revenue, with the Indonesia Operations segment being the largest contributor at ‪7.34 B‬ EUR, and the United States …